JP2004508297A - 糖尿病の治療に有用なｆｂｐアーゼインヒビターおよび抗糖尿病薬の併用剤 - Google Patents

糖尿病の治療に有用なｆｂｐアーゼインヒビターおよび抗糖尿病薬の併用剤 Download PDF

Info

Publication number
JP2004508297A
JP2004508297A JP2002508433A JP2002508433A JP2004508297A JP 2004508297 A JP2004508297 A JP 2004508297A JP 2002508433 A JP2002508433 A JP 2002508433A JP 2002508433 A JP2002508433 A JP 2002508433A JP 2004508297 A JP2004508297 A JP 2004508297A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
aralkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002508433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508297A5 (no
Inventor
パウル・デー・ファン・プーレイ
マーク・ディ・エライオン
藤原　俊彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of JP2004508297A publication Critical patent/JP2004508297A/ja
Publication of JP2004508297A5 publication Critical patent/JP2004508297A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
JP2002508433A 2000-07-06 2001-07-05 糖尿病の治療に有用なｆｂｐアーゼインヒビターおよび抗糖尿病薬の併用剤 Pending JP2004508297A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
PCT/US2001/021557 WO2002003978A2 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Publications (2)

Publication Number Publication Date
JP2004508297A true JP2004508297A (ja) 2004-03-18
JP2004508297A5 JP2004508297A5 (no) 2011-07-07

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002508433A Pending JP2004508297A (ja) 2000-07-06 2001-07-05 糖尿病の治療に有用なｆｂｐアーゼインヒビターおよび抗糖尿病薬の併用剤

Country Status (18)

Country Link
EP (1) EP1372660A2 (no)
JP (1) JP2004508297A (no)
KR (1) KR100854851B1 (no)
CN (2) CN100396283C (no)
AU (2) AU2001273271B2 (no)
BR (1) BR0112212A (no)
CA (1) CA2412142A1 (no)
CZ (1) CZ20035A3 (no)
HU (1) HUP0301830A3 (no)
IL (2) IL153513A0 (no)
MX (1) MXPA02012713A (no)
NO (1) NO20030034L (no)
NZ (1) NZ523227A (no)
PL (1) PL365779A1 (no)
RU (1) RU2328308C2 (no)
SK (1) SK62003A3 (no)
WO (1) WO2002003978A2 (no)
ZA (1) ZA200300044B (no)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064744A1 (ja) * 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited 糖尿病の治療のための医薬組成物
WO2007023754A1 (ja) * 2005-08-22 2007-03-01 Metabasis Therapeuticis Inc. FBPase阻害剤を含有する薬剤
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
EP1112275B9 (en) 1998-09-09 2004-03-10 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
CA2401706A1 (en) 2000-03-08 2001-09-13 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
IL160983A0 (en) 2001-09-24 2004-08-31 Imp College Innovations Ltd Use of pyy for preparation of a medicament for modification of feeding behavior
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
AU2004309279B2 (en) 2003-12-26 2010-07-15 Kyowa Kirin Co., Ltd. Thiazole derivative
EP2089023A2 (en) 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
UY35065A (es) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd Fármaco combinado que comprende gemigliptina y metformina y método para su preparación
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504728A (ja) * 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ，インコーポレイテッド Ａｉｃａリボシドの放出および血液グルコースの低減のための化合物および方法
WO1998039343A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
WO2000014095A1 (en) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69926400T2 (de) * 1998-12-24 2006-05-24 Metabasis Therapeutics Inc., San Diego Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
EP1741447B1 (en) * 2000-01-21 2013-09-18 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504728A (ja) * 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ，インコーポレイテッド Ａｉｃａリボシドの放出および血液グルコースの低減のための化合物および方法
WO1998039343A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
WO2000014095A1 (en) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質
WO2006064744A1 (ja) * 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited 糖尿病の治療のための医薬組成物
WO2007023754A1 (ja) * 2005-08-22 2007-03-01 Metabasis Therapeuticis Inc. FBPase阻害剤を含有する薬剤
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤

Also Published As

Publication number Publication date
WO2002003978A3 (en) 2003-10-16
PL365779A1 (en) 2005-01-10
NO20030034L (no) 2003-03-05
CN101301294A (zh) 2008-11-12
BR0112212A (pt) 2003-12-30
ZA200300044B (en) 2004-05-06
HUP0301830A2 (hu) 2003-11-28
KR100854851B1 (ko) 2008-08-27
CZ20035A3 (cs) 2003-05-14
EP1372660A2 (en) 2004-01-02
HUP0301830A3 (en) 2007-10-29
SK62003A3 (en) 2003-09-11
IL153513A0 (en) 2003-07-06
CN100396283C (zh) 2008-06-25
AU7327101A (en) 2002-01-21
MXPA02012713A (es) 2004-09-10
CN1599612A (zh) 2005-03-23
AU2001273271B2 (en) 2006-01-05
IL153513A (en) 2014-07-31
CA2412142A1 (en) 2002-01-17
WO2002003978A2 (en) 2002-01-17
KR20030031952A (ko) 2003-04-23
NO20030034D0 (no) 2003-01-03
RU2328308C2 (ru) 2008-07-10
NZ523227A (en) 2005-04-29

Similar Documents

Publication Publication Date Title
US20090197836A1 (en) Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes
KR100854851B1 (ko) 당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물
KR100689943B1 (ko) 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물
US20080004226A1 (en) Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
CN101827832B (zh) 作为葡糖激酶活化剂的乙酰胺衍生物、其制备方法及医药应用
AU2001273271A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
SK8892002A3 (en) Novel bisamidate phosphonate prodrugs, process for their preparation and use thereof
CZ20032927A3 (cs) Léčení cukrovky typu 2 inhibitory z dipeptidylpeptidázy IV
EP2351567A2 (en) Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
US20100056460A1 (en) Combination of organic compounds
AU2006201410A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1552850A2 (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080527

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100623

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20100629

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110802